Southern Counties Veterinary Specialists, Ringwood, UK.
J Vet Intern Med. 2020 Mar;34(2):890-892. doi: 10.1111/jvim.15738. Epub 2020 Feb 25.
Idiopathic aplastic pancytopenia is an uncommon disease in dogs which results in pancytopenia and for which an immune-mediated etiology is suspected. A small number of affected dogs reported in the veterinary literature have responded to immunosuppressive medication but the prognosis generally is considered poor with a reported mortality rate of 80%. Reported response rates to immunosuppression alone in affected people are low with overall and complete responses of 65 and 10%, respectively. With the addition of eltrombopag, an orally available thrombopoietin receptor agonist, reported overall and complete response rates in people increase to 94 and 58%, respectively. Herein, we report the use of eltrombopag in a dog with idiopathic aplastic pancytopenia. Eltrombopag was started after no response was seen to treatment with prednisolone and cyclosporine. Complete remission was achieved after the addition of eltrombopag and was sustained after stopping the medication.
特发性再生障碍性全血细胞减少症是一种罕见的犬类疾病，可导致全血细胞减少，疑似免疫介导的病因。在兽医文献中报道的少数受影响的犬只对免疫抑制药物有反应，但预后通常较差，死亡率为 80%。单独使用免疫抑制药物治疗的报告反应率较低，总反应率和完全反应率分别为 65%和 10%。随着口服血小板生成素受体激动剂艾曲波帕的加入，报告的人类总反应率和完全反应率分别增加到 94%和 58%。在此，我们报告了在一例特发性再生障碍性全血细胞减少症犬中使用艾曲波帕。在泼尼松龙和环孢素治疗未见反应后开始使用艾曲波帕。加用艾曲波帕后达到完全缓解，停药后仍持续缓解。
